Reata Pharmaceuticals Closes Class A Common Stock Public Offering
Vinson & Elkins advised Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, in its underwritten follow-on public offering of 2,760,000 shares of its Class A common stock, which included 360,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $183.00 per share.
The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $505.1 million. The offering closed on November 18, 2019.
The V&E corporate team was led by partners Robert Kimball and Brenda Lenahan with assistance from associates Stancell Haigwood, Grace-Ann Duquette and Breanna Kelly. Partner Wendy Salinas and associate Jacob Wight advised on tax issues.
For more information, please speak with our media contacts.